Expression of Cyclin D1, P53 and CDK4 in pancreatic carcinoma

Abstract

AIM: To study the expression of Cyclin D1, P53 and Cyclin-dependent kinase (CDK4) in pancreatic carcinoma, and to explore the relationship of Cyclin D1, P53 and CDK4 with pancreatic carcinoma. METHODS: A total of 48 cases with pancreatic cancer were collected from the First Hospital of Lanzhou University and Dingxi district hospital from July 1997 to January 2004. Immunohisto-chemical staining (S-P method) was used to detect the expressions of Cyclin D1, P53 and CDK4 in 48 cases of pancreatic carcinoma. RESULTS: No significant difference between Cyelin D1, P53 and COK4 expression was detected in different gender, age groups of pancreatic cancer. Positive expression rates of Cyclin D1 and COK4 were significantly higher in the poorly differentiated, lymph node metastasis, clinical stage Ⅲ, Ⅳ phase groups than in well-differentiated, no lymph node metastasis, clinical stage Ⅰ, Ⅱ phase groups (Cyclin D1: χ^2=10.540, 14.225, 5.043, P＜0.01 or 0.05; CD4: χ^2=7.619, 4.006, 5.581, P＜0.05). The P53 positive expression rate was significantly higher in lymphatic metastasis group than the non-lymph node metastasis group (χ^2=6.146, P＜0.05). However, no significant difference in P53 expression was detected between different differentiation groups or between different clinical stage groups. CONCLUSION: As Cyclin D1 is over expressed in pancreatic carcinoma, it can be used as a biomarker for early diagnosis of pancreatic carcinoma. However, P53 and CDK4 play important synergistic roles in pathogenesis and development of pancreatic carcinoma.